APRIL 2017 Deal Watch Review now published.
Margaret has a proven track record in drug discovery & development and deal facilitation within the pharmaceutical industry with over 25 years wide-ranging research and commercial experience in various senior positions at Merck & Co following several years within the NHS.
Margaret is a recent addition to the Medius team following her departure from Merck where she was responsible for the oversight and strategic direction of Merck’s licensing and partnering operation in Europe. During her 8 year tenure Margaret built up an extensive global network of contacts. She was the prime driver in the identification and execution of several major deals including those with Addex Pharmaceuticals: Parkinson’s disease; Schizophrenia and Galapagos NV: Diabetes/Obesity; Inflammatory Diseases; Cardiovascular Disease.
Prior to this Margaret as head of the in vitro pharmacology team played a pivotal role in the development of Merck’s marketed anti-migraine drug Maxalt. Her involvement spanned basic research to post-launch marketing.
Margaret is extremely well connected worldwide at all levels in the industry including large pharma, SMEs, biotech, CROs, academic groups, governmental organisations and the VC community. She is closely linked to key players throughout the international pharma world, covering all aspects of drug discovery, development and commercialisation. She has also served as a committee member of the UK’s Pharmaceutical Licensing Group.
Margaret is a renowned presenter and networker with excellent communication skills. She has regularly presented at international scientific and bio-partnering conferences and has run many workshops.
Margaret’s PhD thesis focused on the pharmacology of 5-HT receptor subtypes. She is a graduate of Reading (BSc) and London (MSc) Universities and has carried out post-graduate work at Stanford University, The London Business School and The Judge Business School, University of Cambridge. She is the author of 66 scientific publications in peer reviewed journals and some 50 abstracts presented at national / international scientific conferences.